FDAnews
www.fdanews.com/articles/72142-genta-aventis-end-genasense-development-pact

Genta, Aventis End Genasense Development Pact

May 10, 2005

Genta and Aventis signed an agreement to end their development and commercialization pact for the cancer drug Genasense. In November, Aventis, part of sanofi-aventis, provided Genta with a notice of termination of the arrangement. The agreement ends the financial obligations of each company, and the line of credit established by Aventis to Genta will be retired. Aventis will also return its current inventory of Genasense to Genta. In addition, Genta will assume responsibility for the clinical trial of Genasense in combination with docetaxel in prostate cancer patients, which is underway in Europe.

The Street (http://www.thestreet.com/_yahoo/stocks/biotech/10222640.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA)